An open-label, multiple ascending dose escalation, phase 1 study will evaluate KSI-501 in patients with diabetic macular edema. an open-label, multiple ascending dose study
Latest Information Update: 08 May 2024
At a glance
- Drugs Tabirafusp tedromer (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
Most Recent Events
- 02 May 2024 According to Kodiak media release,data from this study will be presented at Association for Research in Vision and Ophthalmology 2024 Annual Meeting, being held from May 5-9 in Seattle, Washington.
- 30 Jan 2024 According to a Kodiak Sciences media release, results of this study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting on Saturday, February 3, 2024, at 3:30 PM ET.
- 14 Nov 2023 According to a Kodiak Sciences media release, clinical data are expected to be presented in the first quarter of 2024 at an upcoming scientific meeting.